Medical Genetics seminars
March 2021
Genetic therapies for Huntington’s disease, what does the future hold for neurodegenerative disorders?
Sarah Tabrizi· University College London
Tue, Mar 9 · 17:00 UTC · Online
There are no effective disease-modifying therapies for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis or Huntington’s disease. Huntington’s disease (HD) is a devastating autosomal dominantly inherited neurodegenerative disease and the world’s most common genetic dementia. I will present an overview of important approaches in development for targeting mutant HTT DNA and RNA (Tabrizi et al Neuron 2019), the cause of HD pathogenesis, and the translational pathway from bench to clinic for a HTT targeting antisense oligonucleotide (Tabrizi et al New England Journal of Medicine 2019, Tabrizi, Science 2020) which is now in phase 3 studies. In my talk I will also review some of the genetic approaches in development for other CNS diseases. I will talk a bit about my journey as a clinician scientist and share some of my learnings for young scientists on how to survive a career in science.
February 2021
Desarrollo de tratamientos para síndromes de epilepsia: oportunidades para SYNGAP1
Ana Mingorance PhD· Dracaena Consulting / Fundación Loulou (España)
Fri, Feb 19 · 05:30 UTC · Online
Características generales de la encefalopatía epiléptica y desarrollo en SYNGAP1
Andrés Jiménez Gómez, MD· Joe DiMaggio Children's Hospital (Estados Unidos) -
Fri, Feb 19 · 02:00 UTC · Online
Genome architecture and disease: the 16p11.2 paradigm
Alexandre Reymond· Center for Integrative Genomics, University of Lausanne, Switzerland
Thu, Feb 18 · 12:15 UTC · Online
Lysosomal storage disorders and their unanticipated links to rare and common diseases
Frances Platt· University of Oxford
Mon, Feb 8 · 11:00 UTC · Online
Lysosomal storage diseases are a group of over 70 inherited metabolic disorders, many of which have a neurodegenerative clinical course. Treatments have been developed for a subset of these disorders and are now in routine clinical use. We have found that some neurological and neurodegenerative diseases share unanticipated links to lysosomal storage diseases providing insights into disease pathogenesis. These links also suggest treatments developed for lysosomal disorders may have unanticipated utility in other rare and common diseases.
September 2020
A challenge in neurogenetics: Huntington disease in kids
Ferdinando Squitieri· Fondazione IRCCS Casa Sollievo Sofferenza & CSS-Mendel Institute, Italy
Recorded
July 2020
Exploring the Genetics of Parkinson's Disease: Past, Present, and Future
Andrew Singleton· National Institute on Aging
Tue, Jul 28 · 15:00 UTC · Online
In this talk, Dr Singleton will discuss the progress made so far in understanding the genetic basis of Parkinson’s disease. He will cover the history of discovery from the first identification of disease causing mutations to the state of knowledge in the field today, more that 20 years after that initial discovery. He will then discuss current initiatives and the promise of these for informing the understanding and treatment of Parkinson’s disease. Lastly, Dr Singleton will talk about current gaps in research and knowledge and working together to fill these.
End of results.